FY2027-H1First statedAnnual report
「Against this economic backdrop, in the pharmaceutical industry, a draft public-private investment roadmap for 17 strategic fields was adopted in July 2026, setting out approximately ¥64 trillion in investment in drug discovery and advanced medicine and indicating a direction for focused resource allocation. While medical needs are becoming more diverse and expectations for the development of innovative medicines are rising, challenges include increased research and development costs and longer drug development timelines. Against the backdrop of these policy developments, measures are being advanced to foster drug discovery startups, promote industry-academia-government collaboration and enhance the clinical development environment, and the role to be played by drug discovery ventures such as the company is becoming increasingly important.」
For the first time, the policy and market environment for the pharmaceutical industry is described as including a draft public-private investment roadmap with approximately ¥64 trillion earmarked for drug discovery and advanced medicine, progress in fostering drug discovery startups and promoting industry-academia-government collaboration, and improvements to the clinical development environment.